Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biotechnology company will post earnings of ($4.72) per share for the year. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period in the prior year, the company posted ($1.02) earnings per share.

Several other equities analysts also recently weighed in on ARWR. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Citigroup reduced their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen raised Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Finally, B. Riley reissued a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $43.71.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock traded down $0.52 during mid-day trading on Wednesday, reaching $16.22. 1,466,589 shares of the company were exchanged, compared to its average volume of 1,530,549. The firm has a market cap of $2.24 billion, a PE ratio of -3.14 and a beta of 0.96. The firm's 50-day simple moving average is $14.14 and its two-hundred day simple moving average is $17.29. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $30.41. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,628 shares during the period. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $49,000. Van ECK Associates Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the period. CWM LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the period. Finally, KBC Group NV lifted its holdings in Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after buying an additional 2,132 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the transaction, the chief executive officer now directly owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.